Published in J Invest Dermatol on March 01, 2005
Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ (2008) 2.32
Why is the mortality of bullous pemphigoid greater in Europe than in the US? J Invest Dermatol (2005) 0.77
Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol (2004) 3.63
A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med (2002) 5.58
Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst (2006) 4.95
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol (2007) 3.58
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol (2007) 2.71
Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol (2002) 2.49
A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med (2007) 2.41
Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol (2004) 2.33
Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med (2010) 2.28
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer (2009) 2.26
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15
Hearing thresholds and tympanic membrane sequelae in children managed medically or surgically for otitis media with effusion. Arch Pediatr Adolesc Med (2005) 2.13
B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol (2008) 2.10
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. Eur J Cancer (2012) 2.05
Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol (2011) 2.03
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol (2007) 2.00
Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. Arch Dermatol (2012) 1.97
Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol (2003) 1.94
Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol (2012) 1.94
Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets? Proteins (2003) 1.93
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics (2008) 1.92
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol (2008) 1.81
Estimates of the cancer burden in Europe from radioactive fallout from the Chernobyl accident. Int J Cancer (2006) 1.71
Poor benefit/risk balance of intravenous immunoglobulins in DRESS. Arch Dermatol (2012) 1.71
GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst (2010) 1.68
Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn (2012) 1.66
Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol (2009) 1.66
Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol (2008) 1.64
ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol (2009) 1.62
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol (2011) 1.60
Reading factor: a new bibliometric criterion for managing digital libraries. J Med Libr Assoc (2002) 1.58
Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. Lancet Oncol (2004) 1.57
Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics (2009) 1.53
Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol (2003) 1.53
Interface strategy during noninvasive positive pressure ventilation for hypercapnic acute respiratory failure. Crit Care Med (2009) 1.52
Association between endothelin receptor B nonsynonymous variants and melanoma risk. J Natl Cancer Inst (2005) 1.51
Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma. J Cutan Pathol (2008) 1.50
Distinctive features of melanoma and its management in elderly patients: a population-based study in France. JAMA Dermatol (2013) 1.49
Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol (2008) 1.47
Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: results from a case-control study. J Invest Dermatol (2007) 1.41
Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging (2008) 1.39
Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol (2009) 1.39
Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J (2002) 1.35
Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet J Rare Dis (2012) 1.32
Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol (2002) 1.32
Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol (2013) 1.28
Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population. Hum Mutat (2008) 1.26
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol (2009) 1.26
Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol (2010) 1.22
Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. Am J Epidemiol (2011) 1.21
Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers. Eur J Hum Genet (2011) 1.21
Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol (2012) 1.18
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med (2013) 1.15
Neurological disorders in patients with bullous pemphigoid. Dermatology (2007) 1.14
Stressful life events as a risk factor for inflammatory bowel disease onset: A population-based case-control study. Am J Gastroenterol (2006) 1.13
Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol (2013) 1.12
Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res (2011) 1.12
Complete germline deletion of the STK11 gene in a family with Peutz-Jeghers syndrome. Eur J Hum Genet (2004) 1.11
French people and skin diseases: results of a survey using a representative sample. Arch Dermatol (2003) 1.11
Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol (2004) 1.09
Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol (2011) 1.07
Drug-induced skin, nail and hair disorders. Drug Saf (2007) 1.07
More on Merkel-Cell Carcinoma. N Engl J Med (2016) 1.06
Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol (2011) 1.04
Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol (2006) 1.04
Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol (2005) 1.04
Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs (2005) 1.02
MC1R and PTCH gene polymorphism in French patients with basal cell carcinomas. J Invest Dermatol (2006) 1.00
Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol (2002) 0.99
Agreement between patients' self-report and medical records for vaccination: the PGRx database. Pharmacoepidemiol Drug Saf (2013) 0.99
Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. Arch Pathol Lab Med (2013) 0.98
In vivo confocal microscopic evaluation of corneal changes in chronic Stevens-Johnson syndrome and toxic epidermal necrolysis. Cornea (2009) 0.98
Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study. Pigment Cell Melanoma Res (2012) 0.98
Clinical and sociodemographic characteristics associated with thick melanomas. A population-based, case-case study in France. Arch Dermatol (2012) 0.98
Acute bacterial skin infections and cellulitis. Curr Opin Infect Dis (2007) 0.96
Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol (2002) 0.96
Neurolymphomatosis associated with Sézary syndrome. Arch Dermatol (2009) 0.95
Value of interphase FISH for the diagnosis of t(11:14)(q13;q32) on skin lesions of mantle cell lymphoma. Am J Clin Pathol (2002) 0.95
MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in southern European populations: results from a meta-analysis. Eur J Cancer (2012) 0.95
Impact of STROBE statement publication on quality of observational study reporting: interrupted time series versus before-after analysis. PLoS One (2013) 0.95
No correlation between the molecular subtype of COL1A1-PDGFB fusion gene and the clinico-histopathological features of dermatofibrosarcoma protuberans. J Invest Dermatol (2009) 0.95
Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health (2004) 0.94
BP230- and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol (2004) 0.94
Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression. Biochimie (2005) 0.94
Discriminating nevus and melanoma on paraffin-embedded skin biopsies using FTIR microspectroscopy. Biochim Biophys Acta (2005) 0.93